These three new patents extend protection to include all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the use of these formulations for treating ophthalmic diseases such as dry age related macular degeneration (Dry AMD) and Stargardt’s macular degeneration (SMD). We believe that these three […]

Leer Más "PHASE II CLINICAL TRIALS FOR AMD AND STARGARDT DISEASE"